The possibility that a widely prescribed erectile dysfunction drug could meaningfully interfere with cancer spread reframes how oncologists and patients might think about repurposed pharmaceuticals. The mechanism uncovered here is not about blood flow or nitric oxide signaling in the conventional sense — it points instead to an entirely different biological lever: cholesterol logistics inside the lysosome.
Working across multiple mouse and human cancer models, investigators found that sildenafil and related PDE5a inhibitors trigger an accumulation of cholesterol within lysosomes, effectively starving cancer cells of the membrane cholesterol they need to migrate. The mechanism centers on cGMP binding directly to NPC1, the lysosomal transporter whose loss-of-function mutations cause Niemann-Pick type C disease. By mimicking that pathological blockade pharmacologically, elevated intracellular cGMP prevents cholesterol export from the lysosome. Downstream consequences include disruption of lipid rafts — the cholesterol-rich membrane microdomains critical to invasive signaling — and impaired mitochondrial energy metabolism. Cancer cells showed particular vulnerability because of comparatively low baseline lysosomal gene expression. Combining sildenafil with statins, which block upstream cholesterol biosynthesis, produced additive antimetastatic effects. Retrospective analysis of digital health records found improved survival in sildenafil users, with a dose-dependent enhancement when statins were co-prescribed.
This finding is potentially paradigm-shifting for two reasons. First, it defines a non-canonical cGMP function — direct transporter binding — distinct from classical PKG-mediated signaling, adding a new layer to PDE5 biology. Second, the statin-sildenafil combination creates a metabolic pincer: blocking both supply (biosynthesis) and export (NPC1-mediated trafficking) simultaneously. The retrospective survival data, while inherently confounded by indication and lifestyle factors, lends translational plausibility. Key limitations include the observational nature of the human data, the absence of randomized trial evidence, and uncertainty about whether the cholesterol-trapping effect occurs at clinically achievable sildenafil doses. Prospective trials examining metastasis endpoints in cancer patients prescribed PDE5 inhibitors are now scientifically warranted.